Table 1.
Comparison of preoperative clinical features, shown as M (P25, P75)
| By detection method | By the diameter of adrenal nodules | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | AVS group (N = 66) |
CXCR4 group (N = 23) | F | P | Patients with nodules ≥1 cm (N = 74) |
Patients with nodules 5–10 mm (N = 15) |
F | P |
| Age (year) | 49.00 (40.75, 54.00) | 45.00 (39.00, 51.00) | 5.422 | 0.022* | 48.00 (40.00, 53.00) | 51.00 (40.00,59.00) | 0.326 | 0.570 |
| Sex (male, n (%)) | 33 (50.00) | 11 (47.82) | 0.032 | 0.859 | 33 (44.59) | 11 (78.57) | 2.146 | 0.147 |
| Body mass index (kg/m2) | 23.88 (21.77, 27.39) | 24.09 (19.57, 26.40) | 0.314 | 0.577 | 23.95 (21.50, 27.06) | 24.09 (22.21,24.09) | 1.108 | 0.295 |
| Systolic blood pressure (mmHg)a | 154.00 (140.50, 168.00) | 145.00 (137.00, 155.00) | 2.803 | 0.098 | 150.00 (139.75,163.25) | 155.00 (139.00, 164.00) | 0.709 | 0.402 |
| Diastolic blood pressure (mmHg)a | 101.00 (92.00, 111.25) | 96.00 (94.00, 105.00) | 1.471 | 0.228 | 99.00(93.00,108.25) | 102.00 (92.00, 114.00) | 0.034 | 0.854 |
| History of hypokalaemia, n (%) | 52 (78.78) | 16 (69.56) | 0.794 | 0.375 | 55 (74.32) | 13(86.67) | 1.043 | 0.310 |
| History of hypertension, n (%) | 59 (89.39) | 21 (91.30) | 0.067 | 0.796 | 68 (91.89) | 12(80.00) | 1.043 | 0.310 |
| Maximum systolic blood pressure (mmHg) | 170.00 (150.00, 190.00) | 160.00 (150.00, 170.00) | 0.640 | 0.426 | 170.00 (150.00, 187.75) | 170.00 (145.00,180.00) | 0.022 | 0.882 |
| Maximum diastolic blood pressure (mmHg) | 100.00 (90.00, 110.00) | 100.00 (93.75, 110.00) | 0.405 | 0.526 | 100.00 (90.00, 110.00) | 100.00 (97.00,110.00) | 0.446 | 0.506 |
| Antihypertensive drug DDDb | 1.00 (0.80, 1.60) | 1.00(1.00, 2.40) | 1.952 | 0.166 | 1.00(1.00,1.65) | 1.00 (1.00,2.20) | 0.387 | 0.536 |
| Urea nitrogen (mmol/L) | 4.50 (3.70, 5.30) | 5.20 (3.50, 6.30) | 2.596 | 0.111 | 4.50(3.50,5.97) | 5.00 (3.80,5.60) | 0.148 | 0.701 |
| Serum creatinine (umol/L) | 71.50 (58.25, 84.75) | 78.00 (55.00, 94.00) | 2.022 | 0.159 | 72.00(56.00,87.75) | 80.00 (64.00, 88.00) | 0.030 | 0.864 |
| eGFR [ml/(min.1.73m2)] | 97.74 (82.61, 109.23) | 99.00 (84.06, 106.80) | 0.650 | 0.422 | 98.32(81.59,109.11) | 87.83 (84.79, 109.24) | 0.417 | 0.520 |
| Serum potassium (mmol/L) | 3.48 (3.15, 3.85) | 3.50(3.10, 3.86) | 0.544 | 0.463 | 3.47(3.14,3.81) | 3.79 (3.46,4.10) | 2.760 | 0.101 |
| DRC (mIU/L) | 1.59 (0.78, 3.71) | 1.87 (1.03, 4.05) | 0.434 | 0.512 | 1.48 (0.78, 3.57) | 2.11 (1.23,5.05) | 0.101 | 0.752 |
| PAC (ng/dl) | 27.20 (18.48, 39.55) | 24.70 (15.70, 62.20) | 0.414 | 0.521 | 27.90 (18.27, 53.45) | 21.60 (14.90,27.70) | 1.575 | 0.213 |
| ARR [(ng/dl)/(mIU/L)] | 15.65 (7.15, 46.75) | 17.69 (5.86, 35.64) | 0.564 | 0.455 | 20.22(7.44, 46.75) | 7.52(6.60,15.63) | 1.742 | 0.190 |
| PAC after CCT (ng/dl) | 30.70 (19.00, 43.50) | 19.60 (11.80, 54.90) | 0.091 | 0.764 | 31.25(17.93,48.83) | 22.00(15.80,30.10) | 1.429 | 0.236 |
| PAC after SSIT (ng/dl) | 21.60 (13.80, 32.30) | 16.80 (10.75, 40.20) | 0.454 | 0.503 | 22.00(13.60,34.90) | 20.95 (12.55, 24.05) | 1.024 | 0.315 |
| Bilateral adrenal involvement(Yes, n (%)) | 16 (24.24) | 6 (26.08) | 0.536 | 0.466 | 19 (25.67) | 3 (20.00) | 0.212 | 0.647 |
| Maximum diameter of adrenal nodules (mm) | 14.00 (11.00, 16.00) | 13.00 (11.00, 16.00) | 0.001 | 0.982 | 14.50(12.00,17.00) | 5.00(5.00,5.00) | / | / |
Reference range of general parameters: urea nitrogen: 3.1–8.8 mmol/L; creatinine: 49–88 µmol/L; Serum potassium: 3.5–5.3 mmol/L; eGFR: 80–120 mL/(min.1.73m2)
ARR renin/aldosterone ratio, DDD defined average daily dose of antihypertensive drugs, DRC direct renin concentration, eGFR estimated glomerular filtration rate, PAC plasma aldosterone concentration, CCT captopril challenge test, SSIT seated saline infusion test
*P < 0.05, there was a significant difference
aBlood pressure values were obtained from office measurements
bThe daily maintenance dose of common antihypertensive drugs is defined according to the requirements of (https://www.whocc.no/atc_ddd_index/). The DDD definitions for common antihypertensive drugs in our centre is included in Appendix 2-DDD values of common antihypertensive drugs